Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 19.53
- Piotroski Score 4.00
- Grade Sector Perform
- Symbol (DSGN)
- Company Design Therapeutics, Inc.
- Price $5.58
- Changes Percentage (1.73%)
- Change $0.1
- Day Low $5.43
- Day High $5.71
- Year High $7.77
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $12.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.04
- Trailing P/E Ratio -3.7
- Forward P/E Ratio -3.7
- P/E Growth -3.7
- Net Income $-66,862,000
Income Statement
Quarterly
Annual
Latest News of DSGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors
Institutions' significant holdings in Design Therapeutics (NASDAQ:DSGN) indicate control over its share price. Institutional investors, hedge funds, insiders, and private equity firms all play a role ...
By Yahoo! Finance | 3 months ago
